Trials / Terminated
TerminatedNCT03248141
Understanding Hemophilia A and B Drug Dosage Administration Patterns
UNDERSTANDING HEMOPHILIA A AND B DRUG DOSAGE ADMINISTRATION PATTERNS
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Study Design A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings. 30 sites will enroll approximately 300 patients Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate. Physicians complete a retrospective chart review on each enrolled patient. Patients will complete a one-time study questionnaire.
Detailed description
Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. Subjects currently enrolled into the study have completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hemophilia B standard half-life | Benefix |
| DRUG | Hemophilia B extended half-life | Alprolix |
| DRUG | Hemophilia A standard half-life | Xyntha and other standard half-life agents |
| DRUG | Hemophilia A extended half-life | Eloctate and Adynovate |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2018-03-14
- Completion
- 2018-03-14
- First posted
- 2017-08-14
- Last updated
- 2019-05-20
- Results posted
- 2019-05-20
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03248141. Inclusion in this directory is not an endorsement.